A sudden onset of a pseudo-neurological syndrome after HPV-16/18 AS04-adjuvated vaccine: might it be an autoimmune/inflammatory syndrome induced by adjuvants (ASIA) presenting as a somatoform disorder?

Immunologic Research

Volumn 60, Issue 2-3, 2014, Pages 236-246

  Poddighe, Dimitri ^a   Castelli, Lucia ^a   Marseglia, Gian Luigi ^b   Bruni, Paola ^a  

^a FATEBENEFRATELLI HOSPITAL   (Italy)

^b FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

Author keywords

Adverse event; Autoimmune inflammatory syndrome induced by adjuvants (ASIA); Functional somatoform syndrome; Human papillomavirus; Vaccine

Indexed keywords

ADJUVANT; ANTIDEPRESSANT AGENT; AUTOANTIBODY; BETA2 GLYCOPROTEIN 1 ANTIBODY; CARDIOLIPIN ANTIBODY; PHOSPHOLIPID ANTIBODY; WART VIRUS VACCINE; ALUMINUM HYDROXIDE; ASO4 MIXTURE; LIPID A;

ADOLESCENT; ANXIETY DISORDER; ARTHRALGIA; ARTICLE; AUTOIMMUNE DISEASE; CASE REPORT; CHRONIC FATIGUE SYNDROME; CLINICAL FEATURE; DIZZINESS; ERYTHEMA; FAINTNESS; FEMALE; FOLLOW UP; GAIT DISORDER; HEADACHE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; IMMUNOLOGICAL TOLERANCE; INFLAMMATION; LEG; LIMB DYSESTHESIA; MALAISE; MOTOR DYSFUNCTION; MYALGIA; NEUROLOGIC DISEASE; PARESIS; PARESTHESIA; PRIORITY JOURNAL; PSEUDO NEUROLOGICAL SYNDROME; RASH; SOMATOFORM DISORDER; VACCINATION; ANALOGS AND DERIVATIVES; AUTOIMMUNE DISEASES; IMMUNOLOGY; SOMATOFORM DISORDERS; SYNDROME;

ALUMINUM HYDROXIDE; AUTOIMMUNE DISEASES; FEMALE; HUMANS; INFLAMMATION; LIPID A; PAPILLOMAVIRUS VACCINES; SOMATOFORM DISORDERS; SYNDROME;

EID: 84925491236     PISSN: 0257277X     EISSN: 15590755     Source Type: Journal    
DOI: 10.1007/s12026-014-8575-3     Document Type: Article

References (66)

1. Siegrist CA. Vaccine immunology. In: Vaccines. 6th ed. Philadelphia: Elsevier Press; 2013. p. 14–32.
2. Ada G. Overview of vaccines. In: Vaccine protocols. 2nd ed. Totowa, NJ: Humana Press; 2003. p. 1–18.
3. Edelman R. An overview of adjuvant use. In: Vaccine adjuvants: preparation methods and research protocols. 1st ed. Totowa, NJ: Humana Press; 2000. p. 1–27.
4. Pulendran B, Ahmed R. Immunological mechanisms of vaccination. Nat Immunol. 2011;12(6):509–17.
5. Kuroda E, Coban C, Ishii KJ. Particulate adjuvants and innate immunity: past achievements, present findings and future prospects. Int Rev Immunol. 2013;32:209–20.
6. Schiller JT, Lowy DR. Virus infections and human cancer: an overview. Recent Results Cancer Res. 2014;193:1–10.
7. Malik H, Khan FH, Ahsan H. Human papillomavirus: current status and issues of vaccination. Arch Virol. 2014;159:199–205.
8. Schiller JT, Lowy DR, Markowitz LE. Vaccine immunology. In: Vaccines. 6th ed. Philadelphia: Elsevier Press; 2013. p. 235–56.
9. ® Immunostimulant: adjuvant formulations. In: Vaccine adjuvants: preparation methods and research protocols. London: Humana Press; 2000. p. 273–82.
10. Hutchinson DJ, Klein KC. Human Papillomavirus disease and vaccines. Am J Health Syst Pharm. 2008;65:2105–12.
11. Gatto M, Agmon-Levin N, Soriano A, et al. Human papillomavirus vaccine and systemic lupus erythematosus. Clin Rheumatol. 2013;32:1301–7.
12. Committee to Review Adverse Effects of Vaccines, Institute of Medicine of the National Academies. Human papilloma vaccine. In: Adverse effects of vaccine, evidence and causality. Washington, DC: National Academy Press; 2012. p. 505–24.
13. Plotkin SL, Plotkin SA. A short history of vaccination. In: Vaccines. 6th ed. Philadelphia: Elsevier Press; 2013. p. 1–13.
14. Offit PA, De Stefano F. Vaccine safety. In: Vaccines. 6th ed. Elsevier Press, 2013. p. 1464–1480.
15. Tozzi A. Field evaluation of vaccine safety. Vaccine. 2004;22:2091–5.
16. Galli L, Ballotti S. Gli eventi avversi, le precauzioni, le controindicazioni. In: Le vaccinazioni per la pratica pediatrica. Pisa: Pacini editore; 2006. p. 89–99.
17. Chen RT. Vaccine risks: real, perceived and unknown. Vaccine. 1999;17:41–6.
18. Balofsky A, Agmon-Levin N, Shoenfeld Y. The new H1N1 and HPV vaccines and old fears. Curr Opin Rheumatol. 2010;22:431–6.
19. Pollard KM. Introduction. In: Autoantibodies and autoimmunity: molecular mechanisms in health and disease. Weinheim: Wiley Press; 2006. p. 1–26.
20. Amital H, Shoenfeld Y. Natural autoantibodies, heralding, protecting and inducing autoimmunity. In: Autoantibodies. 2nd ed. Philadelphia: Elsevier Press; 2007. p. 7–12.
21. Shoenfeld Y, Aharon-Maor A, Sherer Y. Vaccination as an additional player in the mosaic of autoimmunity. Clin Exp Rheumatol. 2000;18:181–4.
22. Wraith DC, Goldman M, Lambert PH. Vaccination and autoimmune disease: what is the evidence. Lancet. 2003;362:1659–66.
23. Salemi S, D’Amelio R. Could autoimmunity be induced by vaccination? Int Rev Immunol. 2010;29:247–69.
24. Soldevilla HF, Briones SFR, Navarra SV. Systemic lupus erythematosus following HPV immunization or infection? Lupus. 2012;21:158–61.
25. Grimanldi-Bensouda L, Guillemot D, Godeau B, et al. Autoimmune disorders and quadrivalent human papillomavirus vaccination of young female subjects. J Intern Med. 2013;275:398–408.
26. Goncalves AK, Cobucci RN, Rodrigues HM, Gosson de Melo A, Giraldo PC. Safety, tolerability and side effects of human papillomavirus vaccines: a systematic quantitative review. Braz J Infect Dis. 2014; Epub ahead of print.
27. Pellegrino P, Carnovale V, Pozzi M, et al. On the relationship between human papilloma virus vaccine and autoimmune diseases. Autoimmun Rev. 2014;13:736–41.
28. Karussis D, Petrou P. The spectrum of post-vaccination inflammatory CNS demyelinating syndromes. Autoimmun Rev. 2014;13:215–24.
29. Hanly JC. Diagnosis and management of neuropsychiatric SLE. Nat Rev Rheumatol. 2014;10:338–47.
30. Cervera R, Piette JC, Font J, et al. Anti-phospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1000 patients. Arthritis Rheum. 2002;46:1019–27.
31. Shoenfeld Y. Systemic antiphospholipid syndrome. Lupus. 2003;12:497–8.
32. Voigt K, Nagel A, Meyer B, Langs G, Braukhaus C, Lowe B. Towards positive diagnostic criteria: a systematic review of somatoform disorder diagnoses and suggestions for future classification. J Psycosom Res. 2010;68:403–14.
33. Masuko K, Nakamura H. Functional somatic syndrome: how it could be relevant to rheumatologist. Mod Rheumatol. 2007;17:179–84.
34. Kanaan RA, Lepine JP, Wessley SC. The association or otherwise of the functional somatic syndromes. Psycosom Med. 2007;69:855–9.
35. Hausteiner-Wiehle C, Henningsen P. Irritable bowel syndrome: relations with functional, mental and somatoform disorders. World J Gastroenterol. 2014;20:6024–30.
36. Henningsen P, Zimmermann T, Sattel H. Medically unexplained physical symptoms, anxiety and depression: a meta-analytic review. Psycosom Med. 2003;65:528–33.
37. Anderson G, Berk M, Maes M. Biological phenotypes underpin the physio-somatic symptoms of somatization, depression and chronic fatigue syndrome. Acta Psychiatr Scand. 2014;129:83–97.
38. Theoharides TC, Papaliodis D, Konstantinidou A, Kempuraj D, Clemens A. Chronic fatigue syndrome, mast cells and tricyclic antidepressants. J Clin Psychopharmacol. 2005;25(6):515–20.
39. Fukuda K, Straus SE, Hickie I, et al. The chronic fatigue syndrome: a comprehensive approach to its definition and study. International Chronic Fatigue Syndrome Study Group. Ann Intern Med. 1994;121:953–9.
40. Rosemblum H, Shoenfeld Y, Amital H. The common immunogenic etiology of chronic fatigue syndrome: from infections to vaccines via adjuvants to ASIA syndrome. Infect Dis Clin N Am. 2011;25:851–63.
41. Shoenfeld Y, Agmon-Levin N. ASIA: autoimmune/inflammatory syndrome induced by adjuvants. J Autoimm. 2011;36:4–8.
42. Vera-Lastra O, Medina G, Cruz-Dominguez M, Jara LJ, Shoenfeld Y. Expert Rev Clin Immunol. 2013;9(4):361–73.
43. Steele L, Sastre A, Gorkovich MM, Cook MR. Complex factors in the etiology of Gulf War Syndrome: wartime exposures and risk factors in veteran subgroups. Environ Health Perspect. 2012;120(1):112–8.
44. Zafrir Y, Agmon-Levin N, Shilton T, Shoenfeld Y. Autoimmunity following hepatitis B vaccine as part of the spectrum of Autoimmune(Auto-inflammatory) Syndrome Induced by Adjuvants (ASIA): analysis of 93 cases. Lupus. 2012;21:146–52.
45. Israeli E. Gulf War Syndrome as a part of the autoimmune (autoinflammatory) syndrome induced by adjuvants (ASIA). Lupus. 2012;21:190–4.
46. Hajdu SD, Agmon-Levin N, Shoenfeld Y. Silicone and autoimmunity. Eur J Clin Invest. 2011;41(2):203–11.
47. Israeli E, Agmon-Levin N, Blank M, Shoenfeld Y. Macrophagic Myofasciitis a vaccine(alum) autoimmune-related disease. Clin Rev Allerg Immunol. 2011;41:163–8.
48. Gherardi RK, Authier FJ. Aluminum inclusion macrophagic myofaciitis: a recently identified condition. Immunol Allergy Clin. 2003;23:699–712.
49. Yj Tsai, Gershwin ME. The sick building syndrome: what is it when it is? Compr Ther. 2002;28:140–4.
50. Martinez-Orozco FJ, Vicario JL, Villalibre-Valderrey I, De Andres C, Fernandez-Arquero M, Peraita-Adrados R. Narcolepsy with cataplexy and comorbid immunopathological diseases. J Sleep Res. 2014; Epub ahead of print.
51. Perricone C, Colafrancesco S, Mazor RD, Soriano A, Agmon-Levin N, Shoenfeld Y. Autoimmune/autoinflammatory syndrome induced by adjuvants (ASIA) 2013: unveiling the pathogenic, clinical and diagnostic aspects. J Autoimm. 2013;47:1–16.
52. Blank M, Israeli E, Shoenfeld Y. When APS (Hughes syndrome) met the autoimmune/inflammatory syndrome induced by adjuvants (ASIA). Lupus. 2012;21:711–4.
53. Katzav A, Kivity S, Blank M, Shoenfeld Y, Chapman J. Adjuvant immunization induces high levels of pathogenic antiphospholipid antibodies in genetically prone mice: another facet of the ASIA syndrome. Lupus. 2012;21:210–6.
54. Cruz-Tapias P, Agmon-Levin N, Israeli E, Anaya JM, Shoenfeld Y. Autoimmune (auto-inflammatory) Syndrome Induced by Adjuvants (ASIA): animal models as proof of concept. Curr Med Chem. 2013;20(32):4030–6.
55. Schwarz TF, Huang LM, Medina DM, et al. Four-year follow-up of the immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine when administered to adolescent girls aged 10–14 years. J Adol Health. 2012;50:187–94.
56. Davison K. Autoimmunity in psychiatry. Br J Psych. 2012;200:353–5.
57. Leslie DL, Kozma L, Martina A, et al. Neuropsychiatric disorders associated with streptococcal infection: a case-control study among privately insured children. J Am Acad Child Adolesc Psychiatry. 2008;47(10):1166–72.
58. Hornig M. The role of microbes and autoimmunity in the pathogenesis of neuropsychiatric illness. Curr Opin Rheumatol. 2013;25(4):488–95.
59. Buehler MR. A proposed mechanism for autism: an aberrant neurimmune response manifested as a psychiatric disorder. Med Hypoth. 2011;76:863–70.
60. Kim SE, Chang L. Overlap between functional GI disorders and other functional syndromes: what are the underlying mechanisms? Neurogastroenterol Motil. 2012;24:895–913.
61. Kao CM, Schneyer RJ, Bocchini JA. Child and adolescent immunizations: selected review of recent US recommendations and literature. Curr Opin Pediatr. 2014;26:383–95.
62. Clements CJ. Mass psychogenic illness after vaccination. Drug Safety. 2003;26(9):599–604.
63. Buttery JP, Madin S, Crawford NW, et al. Mass psychogenic response to human papillomavirus vaccination. MJA. 2008;189(5):261–2.
64. Donegan K, Beau-Lejdstrom R, King B, Seabroke S, Thomson A, Bryan P. Bivalent human papillomavirus vaccine and the risk of fatigue syndromes in girls in the UK. Vaccine. 2013;31:4961–7.
65. Agmon-Levin N, Hughes GVR, Shoenfeld Y. The spectrum of ASIA: autoimmune (Auto-inflammatory) Syndrome induced by Adjuvants. Lupus. 2012;21:118–20.
66. Committee to Review Adverse Effects of Vaccines, Institute of Medicine of the National Academies. Summary. In: Adverse effects of vaccine, evidence and causality. Washington, DC: National Academy Press; 2012. p. 1–25.